Cite
HARVARD Citation
Caldart, A. et al. (n.d.). Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience. European journal of cancer. pp. S38-S39. [Online].